Cover Image
市場調查報告書

類胰島素生長因子1受體:開發中產品分析

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365773
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
類胰島素生長因子1受體:開發中產品分析 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 120 Pages
簡介

本報告提供以類胰島素生長因子1受體為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類胰島素生長因子1受體 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Antisense Therapeutics Limited
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Axelar AB
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genmab A/S
  • Immunomedics, Inc.
  • Insmed Incorporated
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Novartis AG
  • PharmAbcine, Inc.
  • ProteoThera, Inc.
  • Silver Creek Pharmaceuticals, Inc.
  • Sucampo Pharmaceuticals, Inc.
  • TyrNovo Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0228TDB

Summary

Global Markets Direct's, 'Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
  • The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Overview
  • Therapeutics Development
    • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Stage of Development
    • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Therapy Area
    • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Indication
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Companies
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Universities/Institutes
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Antisense Therapeutics Limited
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Axelar AB
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Genmab A/S
    • Immunomedics, Inc.
    • Insmed Incorporated
    • Merck & Co., Inc.
    • Merrimack Pharmaceuticals, Inc.
    • Novartis AG
    • PharmAbcine, Inc.
    • ProteoThera, Inc.
    • Silver Creek Pharmaceuticals, Inc.
    • Sucampo Pharmaceuticals, Inc.
    • TyrNovo Ltd.
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drug Profiles
    • 1R-15-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-E1-E1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATL-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AXL-1717 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-3463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-893923 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-754807 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-707 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalotuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganitumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenaldekar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • linsitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-590 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mecasermin rinfabate (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MM-141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize Insulin Like Growth Factor 1 Receptor for Phelan-McDermid Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RU-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize IGF-1R for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit IGF-1R for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit IGF-1R/IR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teprotumumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vesiculin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XGFR-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XGFR-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Dormant Projects
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Discontinued Products
  • Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Featured News & Press Releases
    • Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy
    • May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer
    • Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients
    • Mar 17, 2015: Study suggests precision medicine for adrenal cancer
    • Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium
    • Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer
    • Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting
    • Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics
    • Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer
    • Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer
    • Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease
    • Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy
    • Apr 02, 2013: Axelar Announces Preliminary Results From Phase II Study Demonstrating Efficacy Of AXL1717 In Non-Small Cell Lung Cancer Patients
    • Jan 21, 2013: Axelar Initiates Phase I/II Study Of AXL1717 In Patients With Malignant Astrocytomas In US
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Antisense Therapeutics Limited, H1 2016
  • Pipeline by Astellas Pharma Inc., H1 2016
  • Pipeline by AstraZeneca Plc, H1 2016
  • Pipeline by Axelar AB, H1 2016
  • Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Eli Lilly and Company, H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by Genmab A/S, H1 2016
  • Pipeline by Immunomedics, Inc., H1 2016
  • Pipeline by Insmed Incorporated, H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by PharmAbcine, Inc., H1 2016
  • Pipeline by ProteoThera, Inc., H1 2016
  • Pipeline by Silver Creek Pharmaceuticals, Inc., H1 2016
  • Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Pipeline by TyrNovo Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Dormant Projects (Contd..4), H1 2016
  • Dormant Projects (Contd..5), H1 2016
  • Dormant Projects (Contd..6), H1 2016
  • Discontinued Products, H1 2016
  • Discontinued Products (Contd..1), H1 2016
  • Discontinued Products (Contd..2), H1 2016
  • Discontinued Products (Contd..3), H1 2016
  • Discontinued Products (Contd..4), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top